Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/22/2025 | $40.00 | Market Perform → Outperform | Leerink Partners |
| 8/5/2025 | Hold → Sell | Deutsche Bank | |
| 2/14/2025 | $31.00 → $22.00 | Equal-Weight → Underweight | Morgan Stanley |
| 11/20/2024 | Hold → Reduce | Kepler | |
| 9/9/2024 | $24.00 | Market Perform | Leerink Partners |
| 8/2/2024 | Outperform → Mkt Perform | Raymond James | |
| 3/28/2024 | $41.00 → $31.00 | Neutral → Underperform | BofA Securities |
| 3/7/2024 | $38.00 | Equal-Weight | Morgan Stanley |
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM ((Euronext &, NASDAQ:LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation prioritiesYear-end 2026 cash and financial investments balance expected to be approximately €2BManagement to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ETMechelen, Belgium; May 6, 2026, 22:01 CET; re
Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration ReportThe remuneration of the members of the Board of DirectorsThe appointment of Mr. Henry Gosebruch as Executive DirectorThe appointments of Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, and Mr. Gino Santini as Independent Non-Executive Directors and Mr. Devang Bhuva as Non-Executive DirectorThe re-appointment of the statutory auditor
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV ((Euronext &, NASDAQ:GLPG) ("Galapagos" or the "Company") today an
6-K - Lakefront Biotherapeutics NV (0001421876) (Filer)
424B3 - Lakefront Biotherapeutics NV (0001421876) (Filer)
6-K - GALAPAGOS NV (0001421876) (Filer)
Leerink Partners upgraded Galapagos NV from Market Perform to Outperform and set a new price target of $40.00
Deutsche Bank downgraded Galapagos NV from Hold to Sell
Morgan Stanley downgraded Galapagos NV from Equal-Weight to Underweight and set a new price target of $22.00 from $31.00 previously
Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved. The AGM approved, amongst other items: The Annual Report and the Remuneration ReportThe remuneration of the members of the Board of DirectorsThe appointment of Mr. Henry Gosebruch as Executive DirectorThe appointments of Dr. Jane Griffiths, Ms. Dawn Svoronos, Dr. Neil Johnston, Dr. Paulo Fontoura, and Mr. Gino Santini as Independent Non-Executive Directors and Mr. Devang Bhuva as Non-Executive DirectorThe re-appointment of the statutory auditor
Subject to his election by shareholders, the Board intends to appoint Mr. Santini as Chair, succeeding Jérôme Contamine Mr. Santini will bring extensive corporate governance, business development and industry leadership experience to the Board Mechelen, Belgium; March 26, 2026, 21:02 CET — Galapagos NV ((Euronext &, NASDAQ:GLPG), today announced the proposed appointment of Gino Santini as a Non-Executive Independent Director, with the intention to appoint him as Chair of its Board of Directors, subject to shareholder approval at the Annual Shareholders' Meeting (AGM) on April 28, 2026. If elected, Gino Santini will replace current Director and Chair Jérôme Contamine, whose mandate as a m
Mechelen, Belgium; March 26, 2026, 21:01 CET; regulated information — Galapagos NV ((Euronext &, NASDAQ:GLPG) today published its annual report for the financial year 2025 and announced that its Annual Shareholders' Meeting (AGM) and an Extraordinary Shareholders' Meeting (EGM) will be held sequentially on Tuesday, April 28, 2026 at 14:00 CET and 15:00 CET at Schaliënhoevedreef 20T, 2800 Mechelen, Belgium. The annual report for the financial year 2025, including a review of figures and performance, is available online at https://www.glpg.com/financial-reports and can also be downloaded as PDF. The annual 2025 Form 20-F filing with the SEC is available at www.sec.gov/edgar. Galapagos has t
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM ((Euronext &, NASDAQ:LKFT)Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation prioritiesYear-end 2026 cash and financial investments balance expected to be approximately €2BManagement to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ETMechelen, Belgium; May 6, 2026, 22:01 CET; re
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company will continue to have a majority of its cash remaining for additional strategic transactions and other capital allocation priorities Opportunity to develop a potential first-in-class & best-in-class T cell engager in autoimmune diseases with gamgertamig Management to host conference call today, March 31, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium; March 31, 2026, 7.30 CET; regulated information – Announcement in application of Article 7:97, §4/1 of the BCCA — Galapagos NV ((Euronext &, NASDAQ:GLPG) ("Galapagos" or the "Company") today an
Galapagos intends to enter into a strategic collaboration with Gilead following Gilead's acquisition of Ouro Medicines New partnership structure would achieve meaningfully improved financial terms and flexibility for Galapagos Following this potential transaction, the Company will continue to have a majority of its capital available for additional strategic transactions and other capital allocation priorities Mechelen, Belgium; March 23, 2026, 23:02 CET; regulated information – inside information — Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that, following Gilead's entering into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focuse
SC 13G/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D/A - GALAPAGOS NV (0001421876) (Subject)
SC 13D - GALAPAGOS NV (0001421876) (Subject)